MHRA

hay fever injection_summary.jpg bookmark_icon_off
Legal

Companies told to stop promoting POM treatments for hay fever

Over a dozen companies have been forced to amend their advertising following MHRA action.

2 Min Article

Medicines 2023 1280.jpg bookmark_icon_off
Public health

MHRA looked into wholesaler hoarding claims, says ex-inspector

Former MHRA good distribution practice inspector Peter Coombs said it was “extraordinarily difficult” to gather evidence of hoarding.

1 Min Article

pseudoephedrine_summary.jpg bookmark_icon_off
OTC

MHRA to review safety of pseudoephedrine products

Consumer healthcare body says reported side-effects are “extremely rare” and packaging warnings already in place.

2 Min Article

blurry pharmacy summary.jpg bookmark_icon_off
Public health

Sandimmun Oral Solution batch recalled due to crystals

Batch recalled due to presence of crystals in solution, says MHRA

1 Min Article

Vaccine child 1280.jpg bookmark_icon_off
Public health

Covid vaccine Nuvaxovid passed for use in 12 to 17-year-olds

The MHRA has today announced it has approved Novavax’s Covid vaccine for 12 to 17-year-olds

1 Min Article

common cold summary.jpg bookmark_icon_off
Regulations

MHRA approves POM to P switch for Sudafed Plus Blocked Nose nasal spray

The product will be available from pharmacies without a prescription following the reclassification

1 Min Article

woman sofa summary.jpg bookmark_icon_off
Women's health

MHRA announces ‘landmark’ POM to P switch for Gina 10mcg tablets

The product will be available following a consultation with a pharmacist.

1 Min Article

Recall 1280.jpg bookmark_icon_off
Practice

Quadrant recall batch of mefenamic acid tablets

Batch number 107082 found to have a defective layer of film coating.

1 Min Article

Recall 1280.jpg bookmark_icon_off
Public health

MHRA recalls two drugs in two days

A batch of sodium bicarbonate 1.26 per cent solution for infusion and Paroxetine 40mg film coated tablets were recalled.

1 Min Article

overactive bladder, summary.jpg bookmark_icon_off
Women's health

Mixed reaction to proposed oxybutynin POM to P switch

Some pharmacists have criticised a proposal to reclassify the drug for overactive bladder in women.

2 Min Article

Loading